AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11388531 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (15 ml; 2%) with intravenous saline placebo
Number of subjects: 30
Study 11388531 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (1 mg/kg bolus dose; 25 microg x kg(‐1) x min(‐1))
Number of subjects: 30
Study 11388531 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (intravenous saline placebo)
Number of subjects: 30
Study 9253321 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 72
Study 9253321 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+D (HRT + vitamin D3, 300 IU/day)
Number of subjects: 72
Study 9253321 — intervention group
Group type: EXPERIMENTAL
Intervention: D (vitamin D3, 300 IU/day)
Number of subjects: 72
Study 9253321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium lactate, 500 mg/day)
Number of subjects: 72
Study 9253321 — intervention group
Group type: EXPERIMENTAL
Intervention: D group
Number of subjects: 72
Study 9253321 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 72
Study 9253321 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT and HRT+D groups
Number of subjects: 72
Study 8390368 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 20 mg
Number of subjects: 9
Study 8390368 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 8 mg
Number of subjects: 9
Study 8390368 — intervention group
Group type: COMPARATOR
Intervention: granisetron 3 mg
Number of subjects: 9
Study 8390368 — intervention group
Group type: COMPARATOR
Intervention: saline 20 ml
Number of subjects: 9
Study 3829698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement plus IDU
Number of subjects: 5
Study 3829698 — intervention group
Group type: COMPARATOR
Intervention: IDU alone
Number of subjects: 5
Study 3829698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of PTGG and steroid subconjunctival injection
Number of subjects: 5
Study 3829698 — intervention group
Group type: COMPARATOR
Intervention: Steroid subconjunctival injection alone
Number of subjects: 5
Study 3829698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of PTGG alone
Number of subjects: 5
Study 30758745 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 310
Study 30758745 — intervention group
Group type: COMPARATOR
Intervention: Inotuzumab Ozogamicin (InO)
Number of subjects: 310
Study 29772657 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized Virgin Olive Oil (OVOO) (490 ppm of phenolic compounds and 86 ppm of triterpenes)
Number of subjects: 58
Study 29772657 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) (124 ppm of phenolic compounds and 86 ppm of triterpenes)
Number of subjects: 58
Study 29772657 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Olive Oil (FOO) (487 ppm of phenolic compounds and 389 ppm of triterpenes)
Number of subjects: 58
Study 29772657 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) with at least 124 ppm of phenolic compounds
Number of subjects: 58
Study 29772657 — intervention group
Group type: EXPERIMENTAL
Intervention: All three olive oils (VOO, OVOO, FOO)
Number of subjects: 58
Study 29772657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triterpenes
Number of subjects: 58
Study 27400272 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg atorvastatin
Number of subjects: 20
Study 27400272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24443442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 100
Study 24443442 — intervention group
Group type: COMPARATOR
Intervention: Control (DIPSS cohort)
Number of subjects: 100
Study 22433175 — intervention group
Group type: EXPERIMENTAL
Intervention: Online geriatric assessment
Number of subjects: 270
Study 22433175 — intervention group
Group type: COMPARATOR
Intervention: Live geriatric assessment
Number of subjects: 270
Study 22433175 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource use data for online assessments
Number of subjects: 270
Study 22433175 — intervention group
Group type: COMPARATOR
Intervention: Resource use data for live assessments
Number of subjects: 270
Study 19958646 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate 100 mg once daily (group A)
Number of subjects: 480
Study 19958646 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate 150 mg once daily (group B)
Number of subjects: 480
Study 19958646 — intervention group
Group type: COMPARATOR
Intervention: Compound glycyrrhizin 120 mg once daily (group C)
Number of subjects: 480
Study 17938309 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish adjustable gastric band
Number of subjects: 400
Study 17938309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap-Band
Number of subjects: 400
Study 17938309 — intervention group
Group type: COMPARATOR
Intervention: Both devices (Swedish adjustable gastric band and Lap-Band)
Number of subjects: 400
Study 15727954 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ACTH - normal cortisol
Number of subjects: 65
Study 15727954 — intervention group
Group type: EXPERIMENTAL
Intervention: High ACTH - high cortisol
Number of subjects: 65
Study 15727954 — intervention group
Group type: EXPERIMENTAL
Intervention: High ACTH - low cortisol
Number of subjects: 65
Study 15727954 — intervention group
Group type: COMPARATOR
Intervention: Placebo and steroidogenic inhibitor
Number of subjects: 65
Study 11990404 — intervention group
Group type: EXPERIMENTAL
Intervention: One additional daytime 2-L exchange (intervention group)
Number of subjects: 100
Study 11990404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional exchanges)
Number of subjects: 100
Study 11990404 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing exchanges from 3 to 4 per day
Number of subjects: 100
Study 11990404 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing exchanges from 4 to 5 per day
Number of subjects: 100
Study 11429939 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implants
Number of subjects: 90
Study 11429939 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 90
Study 11429939 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI implants
Number of subjects: 90
Study 11429939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 8134073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide regimen (2 mg/kg IV every 2 hours x 3)
Number of subjects: 40
Study 8134073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron regimen (0.15 mg/kg IV every 4 hours x 3)
Number of subjects: 40
Study 8134073 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but includes diphenhydramine, prochlorperazine, and lorazepam)
Number of subjects: 40
Study 2643902 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms twice a day)
Number of subjects: 8
Study 2643902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31415305 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 0
Study 31415305 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 0
Study 31415305 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 0
Study 28422388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 159
Study 28422388 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 159
Study 28422388 — intervention group
Group type: COMPARATOR
Intervention: Control (silent rest)
Number of subjects: 159
Study 25886090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine plus ranitidine
Number of subjects: 32
Study 25886090 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine plus placebo
Number of subjects: 32
Study 24028597 — intervention group
Group type: EXPERIMENTAL
Intervention: GLUMA Desensitizer PowerGel
Number of subjects: 46
Study 24028597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24028597 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Boost PF 40% gel
Number of subjects: 46
Study 21174144 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine with AS03(A)
Number of subjects: 50
Study 21174144 — intervention group
Group type: COMPARATOR
Intervention: H5N1 vaccine without AS03(A)
Number of subjects: 50
Study 19581353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 19581353 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SAL) 50 microg
Number of subjects: 658
Study 19581353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 658
Study 19581353 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone combination (SFC) (SAL 50 microg/FP 500 microg)
Number of subjects: 658
Study 19581353 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Placebo, SAL, FP, SFC)
Number of subjects: 658
Study 17356088 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst mandibular advancement splint (MAS) treatment for 1 year
Number of subjects: 16
Study 17356088 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 16
Study 15094948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement with synbiotics (PS)
Number of subjects: 129
Study 15094948 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplement without synbiotics (P)
Number of subjects: 129
Study 15094948 — intervention group
Group type: COMPARATOR
Intervention: Fruit-flavored drink (D)
Number of subjects: 129
Study 15604181 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard strength static bipolar magnetic bracelet
Number of subjects: 194
Study 15604181 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak magnetic bracelet
Number of subjects: 194
Study 15604181 — intervention group
Group type: COMPARATOR
Intervention: Non‐magnetic (dummy) bracelet
Number of subjects: 194
Study 11275616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP)
Number of subjects: 60
Study 11275616 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 60
Study 9256938 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 38
Study 9256938 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 38
Study 9256938 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and Saquinavir (combination)
Number of subjects: 38
Study 8341892 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 24
Study 8341892 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24
Study 8341892 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 24
Study 8341892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3577640 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression elastic stockings
Number of subjects: 20
Study 3577640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 20
Study 31235428 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (E-LC)
Number of subjects: 52
Study 31235428 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (D-LC)
Number of subjects: 52
Study 29663492 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine (1:100,000)
Number of subjects: 30
Study 29663492 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine without epinephrine
Number of subjects: 30
Study 27526787 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 150
Study 27526787 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 150
Study 27526787 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 150
Study 24630081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 10 mg daily for 3 months
Number of subjects: 209
Study 24630081 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone acetate (NETA) 10 mg daily for 10 days (control)
Number of subjects: 209
Study 24172250 — intervention group
Group type: EXPERIMENTAL
Intervention: Niños Sanos, Familia Sana intervention (multi-faceted including nutrition, physical activity, economic and art-community engagement)
Number of subjects: 0
Study 24172250 — intervention group
Group type: COMPARATOR
Intervention: Comparison community engagement strategies
Number of subjects: 0
Study 20720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-related visual features
Number of subjects: 0
Study 20720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward feedback response in anterior cingulate cortex
Number of subjects: 0
Study 17924157 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation session led by a PSG technician
Number of subjects: 1481
Study 17924157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orientation session)
Number of subjects: 1481
Study 16640631 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical Approach to Lung Health (PAL) guidelines
Number of subjects: 40
Study 12807271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (24 GPs) involved in the development and implementation of clinical guidelines for acute respiratory infections.
Number of subjects: 54
Study 12807271 — intervention group
Group type: COMPARATOR
Intervention: Moderate intervention group (control group) received a brief educational event and distribution of guidelines.
Number of subjects: 54
Study 12807271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (24 GPs)
Number of subjects: 54
Study 10385495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 6 weeks
Number of subjects: 60
Study 10385495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8682968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil topical solution
Number of subjects: 22
Study 8682968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1843527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokens produced by different speakers presented blocked by speaker
Number of subjects: 0
Study 1843527 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of presentation type (blocked vs. randomized)
Number of subjects: 0
Study 6131682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 64
Study 6131682 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 64
Study 6131682 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (3 times ED90)
Number of subjects: 64
Study 6131682 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (3 times ED90)
Number of subjects: 64
Study 31307412 — intervention group
Group type: EXPERIMENTAL
Intervention: ML program (10-week group sessions focusing on evidence-based parenting practices followed by the MINISTOP application for 6 months)
Number of subjects: 300
Study 28554160 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward arm (n=107) with a payment of S$165.00 and potential rewards of up to S$660 for meeting goals.
Number of subjects: 161
Study 28554160 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=54) receiving the same weight loss program without rewards.
Number of subjects: 161
Study 25888863 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually generate an extra written question on disease mechanisms during small-group work
Number of subjects: 459
Study 25888863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra question generation)
Number of subjects: 459
Study 25888863 — intervention group
Group type: EXPERIMENTAL
Intervention: Male students in the intervention group
Number of subjects: 459
Study 25888863 — intervention group
Group type: EXPERIMENTAL
Intervention: Female students in the intervention group
Number of subjects: 459
Study 23506324 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a vest during medication administration
Number of subjects: 140
Study 23506324 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors and distractions
Number of subjects: 140
Study 23506324 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions with health professionals and patients
Number of subjects: 140
Study 23506324 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in work design
Number of subjects: 140
Study 21153900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary group (DG) receiving daily for 30 months, 1,200 mg of calcium and 7.5 μg of vitamin D(3) for the first 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products
Number of subjects: 40
Study 21153900 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 19618698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target condition (caregiver intervention + care recipient treatment)
Number of subjects: 173
Study 19618698 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-only condition
Number of subjects: 173
Study 19618698 — intervention group
Group type: COMPARATOR
Intervention: Information-only control condition
Number of subjects: 173
Study 17559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-augmented training (SAT) group
Number of subjects: 8
Study 17559386 — intervention group
Group type: COMPARATOR
Intervention: Patient-based training (PBT) group
Number of subjects: 8
Study 15077288 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIT program (high-intensity weight-bearing exercise)
Number of subjects: 309
Study 15077288 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 309
Study 15077288 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIT program
Number of subjects: 309
Study 12153607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 micro g/kg i.v. at 0 min)
Number of subjects: 6
Study 12153607 — intervention group
Group type: COMPARATOR
Intervention: GHRH (1.0 micro g/kg i.v. at 0 min)
Number of subjects: 6
Study 12153607 — intervention group
Group type: COMPARATOR
Intervention: OGTT (100 g oral glucose at -45 min)
Number of subjects: 6
Study 12153607 — intervention group
Group type: COMPARATOR
Intervention: Li-He (Intralipid 10% 250 ml + heparin 2500 U i.v. from -30 to +120 min)
Number of subjects: 6
Study 12153607 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG (0.5 g/kg infused from 0 to +30 min)
Number of subjects: 6
Study 9794328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vista 350 telephone for 6 months
Number of subjects: 35
Study 9794328 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods for recording home monitoring data
Number of subjects: 35
Study 9794328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vista 350 telephone
Number of subjects: 35
Study 7890055 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen of urinary human FSH using a conventional stepwise protocol
Number of subjects: 50
Study 7890055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-dose regimen of urinary human FSH or recombinant human FSH
Number of subjects: 50
Study 2240937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 177
Study 2240937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 177
Study 2240937 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin and Metronidazole
Number of subjects: 177
Study 37853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenorex (40 mg)
Number of subjects: 16
Study 37853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenetylline (50 mg)
Number of subjects: 16
Study 37853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7082858 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum administered intravenously on day 15 of the cytostatic cycle (group I)
Number of subjects: 18
Study 7082858 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum administered intravenously on day 1 of the cytostatic cycle (group II)
Number of subjects: 18
Study 7082858 — intervention group
Group type: COMPARATOR
Intervention: No administration of Corynebacterium parvum (group III)
Number of subjects: 18
Study 31398275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic peptide ligands selected from a randomized 6-mer library using a cysteine-AcrK linker.
Number of subjects: 0
Study 31398275 — intervention group
Group type: COMPARATOR
Intervention: Linear peptide counterparts (implied control).
Number of subjects: 0
Study 29464691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fi O2 0.40
Number of subjects: 65
Study 29464691 — intervention group
Group type: COMPARATOR
Intervention: Fi O2 0.70
Number of subjects: 65
Study 26903214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields (PEMFs)
Number of subjects: 68
Study 26903214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24628390 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d folate supplements
Number of subjects: 69
Study 22713999 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus ibuprofen (AcIBU)
Number of subjects: 141
Study 22713999 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen plus codeine plus caffeine (T3)
Number of subjects: 141
Study 20555373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplement (approximately 1 g EPA and DHA)
Number of subjects: 20
Study 20555373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17907479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone application for 10 seconds on caries lesions
Number of subjects: 79
Study 17907479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment and a root sealant applied to root caries lesions
Number of subjects: 79
Study 17907479 — intervention group
Group type: COMPARATOR
Intervention: Ozone only group
Number of subjects: 79
Study 17907479 — intervention group
Group type: COMPARATOR
Intervention: Sealant only group
Number of subjects: 79